Quick answer: peptide side effects depend on the class of peptide. GLP-1 drugs mainly cause nausea (25% to 29% on Zepbound vs 8% on placebo), diarrhea and vomiting;[1] growth hormone-releasing peptides can cause joint pain, fluid retention and higher blood sugar;[3][4] and bremelanotide causes nausea in 40% of users.[5] Injection site reactions are common across injected peptides. Unapproved peptides add unknown risks from impurities and missing safety data.[7]
“Peptide” covers very different drugs, so there is no single side-effect list. This guide organizes what labels and trials show by class. It is educational and does not replace your prescriber’s advice. More basics are on our peptide basics hub.
Side effects at a glance, by class
| Class (examples) | Most common side effects | Serious risks on the label | Evidence base |
|---|---|---|---|
| GLP-1 drugs (tirzepatide, semaglutide) | Nausea, diarrhea, vomiting, constipation[1] | Thyroid C-cell tumor boxed warning (rodents), pancreatitis, gallbladder disease, severe allergy[1] | Large phase 3 trials |
| GHRH analogues (tesamorelin) | Joint pain, injection site redness and itching, limb pain, swelling, muscle pain[3] | Raised IGF-1, glucose intolerance, fluid retention[3] | Phase 3 trials (HIV lipodystrophy) |
| Ghrelin mimetics (MK-677) | Increased appetite, mild leg swelling, muscle pain[4] | Higher fasting glucose, lower insulin sensitivity[4] | One 2-year trial of 65 older adults; not approved |
| Melanocortin agonists (PT-141) | Nausea, flushing, headache[5] | Transient blood pressure rise, skin darkening[5] | Phase 3 trials |
| Unregulated tanning peptides (Melanotan II) | Not systematically studied | Mole changes in case reports[6] | Case reports only |
| Healing peptides (BPC-157, TB-500) | Unknown in humans | FDA cites impurity and immunogenicity concerns[7] | Mostly animal studies |
GLP-1 drugs
On the Zepbound label, the most common side effects were nausea (25% to 29% vs 8% on placebo), diarrhea (19% to 23% vs 8%), vomiting (8% to 13% vs 2%) and constipation (11% to 17% vs 5%).[1] Wegovy’s label shows a similar GI pattern.[2]
Label warnings include a boxed warning for thyroid C-cell tumors seen in rats (human relevance unknown), acute pancreatitis, gallbladder disease, kidney injury from dehydration, and serious allergic reactions.[1] See our guides on GLP-1 nausea, GLP-1 fatigue and GLP-1 hair loss.
Growth hormone-releasing peptides
Tesamorelin stimulates the body’s own growth hormone. Its label lists joint pain, injection site redness and itching, limb pain, swelling and muscle pain as the most common effects.[3] It also warns that IGF-1 rises: after 26 weeks, 47% of patients had IGF-1 above 2 standard deviation scores. Glucose intolerance or diabetes may develop, so glucose is checked before and during treatment.[3]
MK-677 (ibutamoren), an oral ghrelin mimetic, is not FDA-approved. In a 2-year randomized trial of 65 healthy adults aged 60 to 81, it raised growth hormone and IGF-1 to young-adult levels. The most frequent side effects were increased appetite that faded within months and mild, temporary leg swelling and muscle pain. Fasting glucose rose by about 5 mg/dL, and insulin sensitivity fell.[4] Related peptides such as ipamorelin and CJC-1295 have much less human safety data.
Melanocortin peptides
Bremelanotide (Vyleesi) is approved for low sexual desire in premenopausal women. In pooled phase 3 trials, nausea occurred in 40% vs 1.3% on placebo, flushing in 20.3% vs 0.3%, and headache in 11.3% vs 1.9%.[5] Nausea usually began within an hour and improved for most people by the second dose. The label also warns of a temporary rise in blood pressure after each dose and focal skin darkening in about 1% of users.[5] The trials were funded by the drug’s developers.[9]
Melanotan I and II are unapproved tanning peptides. A dermatology review found growing case reports of changes in existing moles and new atypical moles, plus four reports of melanoma during or shortly after use, though a causal link is not proven.[6]
Unapproved and “research” peptides
For most peptides sold online, no one has measured side effects in controlled human trials. FDA has placed several, including BPC-157, on its list of substances that may pose significant safety risks in compounding, citing possible immune reactions and impurity concerns.[7] Product quality adds risk: in a 2024 study of semaglutide bought from online sellers without a prescription, every vial tested contained bacterial endotoxin and purity was far below the claim.[8]
Risks shared by all injected peptides
Some problems come from injecting rather than from the specific molecule:
- Injection site reactions. Redness, itching and swelling are listed on most injected peptide labels, from about 1.4% of people on Wegovy to 25% on Egrifta SV in the first 26 weeks.[2][3]
- Allergic reactions. Labels for tirzepatide and semaglutide report rare serious hypersensitivity, including anaphylaxis and angioedema.[1][2]
- Dosing errors. Confusion between milligrams, milliliters and syringe units can lead to large overdoses with vial-based products. Our guide on how to calculate peptide dosage explains the math.
- Infection. Reused needles, non-sterile products or poor technique can cause skin infections. See how to inject peptides subcutaneously.
- Contamination. Endotoxin in a product can cause fever and chills soon after a dose; the 2024 online semaglutide study found it in every vial tested.[8]
These shared risks are much lower with approved products made to pharmaceutical standards, and much less predictable with unregulated ones.
How to track and manage side effects, step by step
- Know your product’s label. Read the patient information for the common and serious effects.
- Keep a symptom log with the date, dose, time and what you noticed.
- Report new symptoms to your prescriber rather than changing the dose yourself.
- Get the monitoring your label calls for, such as glucose or IGF-1 checks.[3]
- Check the injection site separately. Our guide to peptide injection site reactions explains what is normal.
- Report serious problems to FDA MedWatch (1-800-FDA-1088) or via your clinician.
For more on whether stopping and restarting changes these risks, see peptide cycling.
